To include your compound in the COVID-19 Resource Center, submit it here.

NIAID exercises option to develop MGD014 from MacroGenics

In early September, MacroGenics Inc. (NASDAQ:MGNX) said NIH's National Institute of Allergy and

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE